Know Cancer

forgot password

An Open-Label Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

Phase 1
18 Years
Not Enrolling
Advanced Solid Tumors

Thank you

Trial Information

An Open-Label Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor
(VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2,
and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong
antiangiogenesis and antitumor activity.

This study is an open-label, non-randomized, exploratory single-arm trial evaluating the ECG
and pharmacokinetic (PK)-ECG relationship, if any, of tivozanib in subjects with advanced
solid tumors.

The purpose of this study is to evaluate the ECG intervals and morphology following
treatment with tivozanib in subjects with advanced solid tumors and to determine the
relationship, if any, of the change in QTc duration with serum concentration of tivozanib
over time in subjects with advanced solid tumors.

Inclusion Criteria

Inclusion Criteria

- Males or females, ≥18 years of age;

- Diagnosis of an advanced solid tumor malignancy with histological or cytological

- Advanced malignancy, metastatic or unresectable, that has recurred or progressed
following standard therapy or failed standard therapy; or for which no standard
therapy currently exists; or for which subject is not a candidate, or is unwilling to
undergo standard therapy;

- Tumor is not currently amenable to curative surgical intervention;

- Recovery from the effects of any prior surgery, radiotherapy, or systemic
antineoplastic therapy;

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and life
expectancy ≥ 3 months;

- Well controlled thyroid function, in the opinion of the Investigator;

- Able to comprehend and willing to sign an Informed Consent Form (ICF) and able to
adhere to dose and visit schedule.

Exclusion Criteria

- Women who are breast-feeding, pregnant, or intend to become pregnant;

- Primary central nervous system (CNS) malignancies or CNS metastases; subjects with
previously treated brain metastasis will be allowed if the brain metastasis have been
stable without steroid treatment for at least 3 months following prior treatment
(radiotherapy or surgery);

- Clinically significant cardiac disease (New York Heart Association class > 2)
including unstable angina, acute myocardial infarction within 6 months of Day 1,
congestive heart failure, or arrhythmia requiring therapy, with the exception of
extra systoles or minor conduction abnormalities, per Investigator judgment;

- Uncontrolled hypertension: systolic blood pressure > 150 mmHg or diastolic blood
pressure > 100 mmHg on 2 or more antihypertensive medications, documented on 2
consecutive measurements taken at least 24 hours apart;

- Baseline ECG, QTcF > 480 ms. If the screening QTcF is > 480 ms, this may be repeated
once and if the QTcF is ≤ 480 ms the subject can be enrolled;

- Any of the following hematologic abnormalities:

• hemoglobin < 9.0 g/dL;

• Absolute neutrophil count < 1500 per mm3;

- platelet count < 100,000 per mm3;

- INR > 1.5 x upper limit of normal (ULN);

- Any of the following serum chemistry or urine abnormalities:

• total bilirubin > 1.5 × ULN (or > 2.5 × ULN for subjects with Gilbert's syndrome);

- AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis);

- alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone

- creatinine > 2.0 × ULN;

- proteinuria > 3+ by urinalysis;

- Non healing wound, bone fracture, or skin ulcer;

- Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other
gastrointestinal condition with increased risk of perforation; history of abdominal
fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks
prior to administration of first dose of study drug;

- Serious/active infection or infection requiring parenteral antibiotics or antifungal

- Inadequate recovery from any prior surgical procedure or major surgical procedure
within 4 weeks prior to administration of first dose of study drug;

- Significant thromboembolic or vascular disorders or surgery within 6 months prior to
administration of first dose of study drug, including but not limited to:

• deep vein thrombosis;

• pulmonary embolism;

• cerebrovascular accident or transient ischemic attack;

• peripheral arterial ischemia > Grade 2;

• coronary or peripheral artery bypass graft;

- Significant bleeding disorders within 6 months prior to administration of first dose
of study drug, including but not limited to:

• hematemesis, hematochezia, melena or other gastrointestinal bleeding ≥ Grade 2;

- hemoptysis or other pulmonary bleeding ≥ Grade 2;

- hematuria or other genitourinary bleeding ≥ Grade 2;

- Currently active second primary malignancy, including hematologic malignancies
(leukemia, lymphoma, multiple myeloma, etc), other than non melanoma skin cancers,
non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular
carcinoma in situ of the breast. Subjects are not considered to have a currently
active malignancy if they have completed anti-cancer therapy and have been disease
free for >2 years;

- History of genetic or acquired immune suppression disease such as human
immunodeficiency virus (HIV), subjects on immune suppressive therapy for organ

- Life-threatening illness or organ system dysfunction compromising safety evaluation;

- Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that
severely affects the absorption of tivozanib, major resection of the stomach or small
bowel, or gastric bypass procedure;

- Psychiatric disorder or altered mental status precluding informed consent or
necessary testing;

- History of significant hypersensitivity, intolerance, or allergy to any drug
compound, food, or other substance, unless approved by the Investigator;

- Use of Seville orange- or grapefruit-containing foods or beverages within 72 hours
prior to Day 1;

- Poor venous access;

- Any acute or chronic condition that, in the opinion of the Investigator, would limit
the subject's ability to complete and/or participate in this clinical study;

- Sexually active male and pre-menopausal female subjects (and their partners) unless
they agree to use adequate contraceptive measures, while on study and for 30 days
after the last dose of study drug. All fertile male and female subjects (and their
partners) must agree to use a highly effective method of contraception. Highly
effective birth control includes (a) IUD plus one barrier method; or (b) two barrier
methods. Effective barrier methods are male or female condoms, diaphragms, and
spermicides (creams or gels that contain a chemical to kill sperm). Note: Oral,
implantable, or injectable contraceptives may be affected by cytochrome P450
interactions, and are not considered effective for this study.

Drugs and Other Treatments to be Excluded

Prohibited 4 weeks prior to first dose and for the duration of the study:

- Chemotherapy, biological therapy (including cytokines, signal transduction inhibitors,
monoclonal antibodies), immunotherapy, experimental therapy or any other therapy for
treatment of advanced solid tumors;

- Systemic hormonal therapy, with the exception of: i. hormonal therapy for appetite
stimulation or contraception; ii. nasal, ophthalmic, inhaled and topical steroid
preparations; iii. androgen suppression therapy for non-metastatic prostate carcinoma; iv.
hormone replacement therapy for conditions such as adrenal insufficiency, hypothyroidism,
etc.; v. low-dose maintenance steroid therapy (equivalent of prednisone ≤ 10 mg/day) for
other conditions;

Prohibited 3 weeks prior to first dose and for the duration of the study:

- Treatment with radiotherapy (limited radiotherapy involving ≤ 25% of bone marrow may be
allowed for palliative purposes after consultation with the medical monitor, treatment
with study drug must be stopped during radiotherapy);

Prohibited 2 weeks prior to first dose and for the duration of the study:

- Herbal preparations/supplements/topical applications (except for daily
multivitamin/mineral supplement not containing herbal components);

- Treatment with CYP3A4 inducers or inhibitors (see Appendix C for examples);

Prohibited 1 week prior to first dose and for the duration of the study:

- Treatment with full dose oral anticoagulants such as warfarin, acenocoumarol,
fenprocoumon, or similar agents. If previously receiving these types of agents, a minimum
washout of 1 week and documented PT of < 1.5 × ULN will be required prior to start of
therapy. Full dose anticoagulation with low molecular weight heparin or unfractionated
heparin administered subcutaneously is allowed. Low dose oral anticoagulation (eg, 1-2
mg/day warfarin) is allowed provided PT remains < 1.5 × ULN during the study.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Change from baseline in QTcF

Outcome Time Frame:

22 days

Safety Issue:


Principal Investigator

Dennis Vargo, MD

Investigator Role:

Study Director

Investigator Affiliation:

AVEO Pharmaceuticals, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

October 2010

Completion Date:

July 2011

Related Keywords:

  • Advanced Solid Tumors
  • AV-951
  • tivozanib
  • QTc
  • advanced solid tumors
  • pharmacokinetics
  • Neoplasms



Florida Cancer SpecialistsFort Myers, Florida  33901
Associates in Oncology/HematologyRockville, Maryland  20850
TGEN Clinical Research Service at Scottsdale HealthcareScottsdale, Arizona  85258
Horizon Oncology Research, Inc.Lafayette, Indiana  
Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMCMetairie, Louisiana  
Oklahoma University Cancer Institute (OUCI)Oklahoma City, Oklahoma  
Tennessee OnocologyNashville, Tennessee  
Multicare Research Institute/Tacoma General HospitalTacoma, Washington